Topics

FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma

08:10 EST 28 Nov 2018 | FDA

The FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

Original Article: FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma

NEXT ARTICLE

More From BioPortfolio on "FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...